Skip to main navigation
Orchestra BioMed logo

Close

Investor Relations
  • Who We Are
    • Our Approach
    • Our People
    • Careers
  • Our Innovations
    • Pipeline
    • Therapeutic Areas
    • Virtue® SAB
    • BackBeat CNT™
    • FreeHold Retractors
  • Investor Relations
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Leadership Team
    • Board of Directors
    • Committee Composition
  • Financial & Filings
    • SEC Filings
    • Annual Reports and Proxy Satements
  • IR Resources
    • Email Alerts
    • Contact IR
  • Contact Us
Menu - sns
Twitter Linkedin

Investor Relations

Nasdaq: OBIO

Vision

To accelerate the delivery of medical innovations to patients through risk-reward sharing partnerships

Company Profile

Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Our partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products we develop. Orchestra BioMed’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy™ (CNT) for the treatment of hypertension, a significant risk factor for death worldwide, and Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide.

Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo Corporation, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed has additional product candidates and plans to potentially expand its product pipeline through acquisitions, strategic collaborations, licensing, and organic development.

Stock Quote

NASDAQ: OBIO

Orchestra BioMed (Common Stock)

Price

Change

Volume

Data Provided by Refinitiv. Minimum 15 minutes delayed.

View Details

View Details
Corporate Presentation

Corporate Presentation


view more

Corporate Presentation


view more
Press Releases

Press Releases

Read our latest company news
view more

Press Releases

Read our latest company news


view more
Events

Events

Barclays Global Healthcare Conference
Mar 14, 2023 at 8:30 AM EDT
Oppenheimer’s 33rd Annual Healthcare Conference
Mar 13, 2023 at 4:00 PM EDT

view more

Events

Barclays Global Healthcare Conference
Mar 14, 2023 at 8:30 AM EDT
Oppenheimer’s 33rd Annual Healthcare Conference
Mar 13, 2023 at 4:00 PM EDT

view more


view more
Orchestra BioMed logo
  • Footerlink - who we are

    Who We Are Our Approach Our People Careers
  • Footerlink - our innovations

    Our Innovations Pipeline Therapeutic Areas Virtue® SAB BackBeat CNT™ FreeHold Retractors
  • Footerlink - news & events

    Investor Relations Overview News & Events Stock Information Corporate Governance Financial & Filings IR Resources
  • Footerlink - contact us

    Contact Us
Menu - sns
Twitter Linkedin

© 2023 Orchestra BioMed Inc. Virtue®, BackBeat CNT™ FreeHold Duo®, FreeHold Trio® and Orchestra BioMed™ are trademarks of Orchestra BioMed.
All other trademarks are trademarks of their respective owners.
SM-0020 Rev 01

Btn - disclaimer

Disclaimer